Target intelligence / Profile preview

Complement component C6 (C6)

Target
C6
Molecular classification
Complement protein, Membrane attack complex/perforin (MACPF) family, Single-chain plasma glycoprotein, Soluble serum protein
01

Overview

Complement component C6 is a single-chain plasma glycoprotein composed of 913 amino acids, essential for the assembly and function of the membrane attack complex (MAC) in the terminal pathway of complement activation. C6 binds non-proteolytically to C5b to form the C5b-6 complex, nucleating MAC assembly, followed by recruitment of C7, C8, and multiple C9 molecules. The MAC forms lytic pores in pathogen membranes, providing innate immunity through direct cell killing. Structurally, C6 is a member of the membrane attack complex/perforin (MACPF) superfamily, sharing domain organization and sequence similarity with C7, C8, and C9. C6 has emerging roles in non-lytic signaling, inflammation, cancer, and neurodegeneration. Inhibiting C6 offers a targeted therapeutic strategy to block cell lysis while preserving upstream complement functions such as opsonization and chemotaxis, but raises concerns about infection risk due to impaired terminal complement activity[1][2][3].

Other names
Complement C6C6complement component 6complement component C6sixth component of complement
02

Mechanism of action

Inhibition of MAC assembly (by blocking the interaction of C6 with C5b or subsequent MAC components); Prevention of pore formation and complement-mediated cytolysis

03

Biological functions

Formation of membrane attack complex (MAC)Direct cell lysis by pore formationImmune defense against bacteria and pathogensInflammatory signaling (when sublytic)
04

Disease associations

Autoimmune and inflammatory diseasesInfectionNeurodegenerative disordersCancerCongenital deficiencies
05

Safety considerations

Increased susceptibility to Neisseria infections (e.g., Neisseria meningitidis) if C6 is deficient or therapeutically inhibitedPotential impairment of immune defense against certain pathogensRisk of compromised host defense if complement inhibition is excessive
06

Interacting drugs

No approved or late-stage drugs specifically inhibit C6, but drugs targeting the terminal complement pathway (such as those targeting C5) would affect downstream C6 function.

1 more in the full profile.

07

Biomarkers

C6 complement levelsC5b-9 (MAC) deposition

Beyond the preview

Go deeper on Complement component C6 (C6).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Complement component C6 (C6).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call